Business Description
![Sanofi SA Sanofi SA logo](https://static.gurufocus.com/logos/0C000008WL.png?14)
Sanofi SA
NAICS : 325412
SIC : 2834
ISIN : FR0000120578
Share Class Description:
XTER:SNW: Ordinary SharesCompare
Compare
Traded in other countries / regions
0O59.UKSNY.USASAN.FranceSNW.Germany1SAN.ItalySNY.MexicoSANO.AustriaSNW.Bulgaria IPO Date
1999-12-20Description
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.49 | |||||
Equity-to-Asset | 0.59 | |||||
Debt-to-Equity | 0.25 | |||||
Debt-to-EBITDA | 1.46 | |||||
Interest Coverage | 15.77 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 1.89 | |||||
Beneish M-Score | -2.54 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.6 | |||||
3-Year EBITDA Growth Rate | -10.9 | |||||
3-Year EPS without NRI Growth Rate | 2 | |||||
3-Year FCF Growth Rate | 10.8 | |||||
3-Year Book Growth Rate | 2.5 | |||||
Future 3-5Y EPS without NRI Growth Rate | 6.86 | |||||
Future 3-5Y Total Revenue Growth Rate | 5.2 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 35.46 | |||||
9-Day RSI | 37.95 | |||||
14-Day RSI | 40.8 | |||||
6-1 Month Momentum % | 1.02 | |||||
12-1 Month Momentum % | -8.3 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.27 | |||||
Quick Ratio | 0.87 | |||||
Cash Ratio | 0.37 | |||||
Days Inventory | 344.04 | |||||
Days Sales Outstanding | 66.24 | |||||
Days Payable | 285.65 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 4.3 | |||||
Dividend Payout Ratio | 0.6 | |||||
3-Year Dividend Growth Rate | 4.2 | |||||
Forward Dividend Yield % | 4.3 | |||||
5-Year Yield-on-Cost % | 5.01 | |||||
Shareholder Yield % | 6.02 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 69.35 | |||||
Operating Margin % | 22.38 | |||||
Net Margin % | 11.63 | |||||
FCF Margin % | 15.58 | |||||
ROE % | 7.32 | |||||
ROA % | 4.28 | |||||
ROIC % | 7.58 | |||||
ROC (Joel Greenblatt) % | 63.22 | |||||
ROCE % | 7.67 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 20.38 | |||||
Forward PE Ratio | 11.44 | |||||
PE Ratio without NRI | 14.84 | |||||
Shiller PE Ratio | 16.29 | |||||
Price-to-Owner-Earnings | 13.17 | |||||
PEG Ratio | 2.47 | |||||
PS Ratio | 2.37 | |||||
PB Ratio | 1.48 | |||||
Price-to-Tangible-Book | 349.56 | |||||
Price-to-Free-Cash-Flow | 15.21 | |||||
Price-to-Operating-Cash-Flow | 10.73 | |||||
EV-to-EBIT | 15.24 | |||||
EV-to-Forward-EBIT | 10.84 | |||||
EV-to-EBITDA | 9.45 | |||||
EV-to-Forward-EBITDA | 8.95 | |||||
EV-to-Revenue | 2.56 | |||||
EV-to-Forward-Revenue | 2.48 | |||||
EV-to-FCF | 16.46 | |||||
Price-to-Projected-FCF | 0.87 | |||||
Price-to-Median-PS-Value | 0.83 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.49 | |||||
Price-to-Graham-Number | 15.12 | |||||
Earnings Yield (Greenblatt) % | 6.56 | |||||
FCF Yield % | 6.6 | |||||
Forward Rate of Return (Yacktman) % | 11.84 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sanofi SA Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 46,444 | ||
EPS (TTM) (€) | 4.3 | ||
Beta | 0.58 | ||
Volatility % | 19.47 | ||
14-Day RSI | 40.8 | ||
14-Day ATR (€) | 1.458808 | ||
20-Day SMA (€) | 89.12 | ||
12-1 Month Momentum % | -8.3 | ||
52-Week Range (€) | 80.8 - 104.3 | ||
Shares Outstanding (Mil) | 1,251.03 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Sanofi SA Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Sanofi SA Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Sanofi SA Frequently Asked Questions
What is Sanofi SA(XTER:SNW)'s stock price today?
The current price of XTER:SNW is €87.39. The 52 week high of XTER:SNW is €104.30 and 52 week low is €80.80.
When is next earnings date of Sanofi SA(XTER:SNW)?
The next earnings date of Sanofi SA(XTER:SNW) is 2024-07-25.
Does Sanofi SA(XTER:SNW) pay dividends? If so, how much?
The Dividend Yield %  of Sanofi SA(XTER:SNW) is 4.3% (As of Today), Highest Dividend Payout Ratio of Sanofi SA(XTER:SNW) was 0.82. The lowest was 0.45. And the median was 0.61. The  Forward Dividend Yield % of Sanofi SA(XTER:SNW) is 4.3%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |